2012
DOI: 10.1016/j.lungcan.2011.05.022
|View full text |Cite
|
Sign up to set email alerts
|

Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2

Citation Types

3
89
0
3

Year Published

2014
2014
2024
2024

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 87 publications
(95 citation statements)
references
References 30 publications
3
89
0
3
Order By: Relevance
“…These patients were young (median age 58 years), mostly non-smokers (64%), in very good or good performance status (91%), and received EGFR-TKIs treatment mainly in the second-line (74%) Patients showed excellent overall response rates to erlotinib and gefitinib (77 and 74.5%, respectively) (13). However, Kim et al showed the drugs were not as efficient in a randomized phase II study of 96 Asian patients with advanced NSCLC: In the erlotinib-and gefitinib-treatment arms the response rates were 40 and 48%, and the median PFS was only 3.1 and 4.9 months, respectively (6). The authors concluded that the reason for treatment failure was including patients with unknown EGFR gene mutations with at least two out of three clinical factors associated with a higher incidence of EGFR gene mutations (6).…”
Section: Univariate Analysis Multivariate Analysis Median Pfs -------mentioning
confidence: 99%
See 3 more Smart Citations
“…These patients were young (median age 58 years), mostly non-smokers (64%), in very good or good performance status (91%), and received EGFR-TKIs treatment mainly in the second-line (74%) Patients showed excellent overall response rates to erlotinib and gefitinib (77 and 74.5%, respectively) (13). However, Kim et al showed the drugs were not as efficient in a randomized phase II study of 96 Asian patients with advanced NSCLC: In the erlotinib-and gefitinib-treatment arms the response rates were 40 and 48%, and the median PFS was only 3.1 and 4.9 months, respectively (6). The authors concluded that the reason for treatment failure was including patients with unknown EGFR gene mutations with at least two out of three clinical factors associated with a higher incidence of EGFR gene mutations (6).…”
Section: Univariate Analysis Multivariate Analysis Median Pfs -------mentioning
confidence: 99%
“…However, Kim et al showed the drugs were not as efficient in a randomized phase II study of 96 Asian patients with advanced NSCLC: In the erlotinib-and gefitinib-treatment arms the response rates were 40 and 48%, and the median PFS was only 3.1 and 4.9 months, respectively (6). The authors concluded that the reason for treatment failure was including patients with unknown EGFR gene mutations with at least two out of three clinical factors associated with a higher incidence of EGFR gene mutations (6). Similarly, in a recent randomized phase III study of 562 pretreated patients with lung adenocarcinoma (including 401 with EGFR mutations), the response rates were 44 and 46% and the median PFS was 7.5 and 6.5 months in erlotinib-and gefitinib-treatment arms, respectively (14).…”
Section: Univariate Analysis Multivariate Analysis Median Pfs -------mentioning
confidence: 99%
See 2 more Smart Citations
“…Both gefitinib and erlotinib showed activity and tolerable toxicity profiles. 144 Several randomized studies that compared an EGFR-TKI versus chemotherapy in unselected or EGFR wild-type patients are summarized in Table 5 and Table 6. All of these studies indicate a marginal or detrimental effect of EGFR TKIs on PFS, especially in EGFR wild-type patients, without registering any difference in terms of OS.…”
mentioning
confidence: 99%